Comparative Pharmacology
Head-to-head clinical analysis: BERUBIGEN versus VI TWEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BERUBIGEN versus VI TWEL.
BERUBIGEN vs VI-TWEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BERUBIGEN (cyanocobalamin) is a form of vitamin B12 that acts as a coenzyme for methylmalonyl-CoA mutase and methionine synthase, essential for DNA synthesis, fatty acid metabolism, and myelin production. It promotes red blood cell maturation and neurologic function.
Hydroxocobalamin is converted to methylcobalamin and adenosylcobalamin, which act as cofactors for methionine synthase and methylmalonyl-CoA mutase, essential for DNA synthesis, myelin formation, and hematopoiesis. It is also a nitric oxide (NO) scavenger, reducing NO-mediated vasodilation in cyanide toxicity.
1000 mcg intramuscularly or deep subcutaneous once daily for 1 week, then 1000 mcg weekly for 1 month, then 1000 mcg monthly for life.
1000 mcg intramuscularly once daily for 5-7 days, then 1000 mcg intramuscularly once weekly for 4 weeks, followed by 1000 mcg intramuscularly once monthly.
None Documented
None Documented
Terminal elimination half-life: ~6-7 days (range 5-10 days). Clinically signifies slow clearance; repeated dosing leads to accumulation in liver stores.
Terminal elimination half-life is approximately 6 days (range 4-10 days) in patients with normal renal function; prolonged in renal impairment (up to 40 days in anuria).
Primarily renal (50-90% of absorbed dose as unchanged drug via glomerular filtration); minor biliary/fecal (<10%) and negligible pulmonary elimination.
Primarily renal: 50-98% of a dose excreted unchanged in urine; biliary/fecal elimination accounts for <2%.
Category C
Category C
Vitamin B12
Vitamin B12